



THE  
BLADDER CANCER  
COMPANY

## Photocure ASA – Repurchase of restricted shares

Oslo, Norway, 12 May 2020: Photocure ASA ("**Photocure**" or the "**Company**") has on 12 May 2021 repurchased a total of 5,344 own shares. The shares were restricted shares and are repurchased pursuant to the terms of the Company's long term incentive program and due to the resignation of one of the former participants in the incentive program.

The Company has repurchased the shares on the following terms:

- 3,803 shares at a price per share of NOK 13.94 equal to 67% of share price of NOK 20.81 per share on grant day 7 May 2018.
- 1,541 shares at a price per share of NOK 0 per share equal to 0% of the average volume weighted price of NOK 30.91 per share on grant day 13 May 2020.

After the acquisition, Photocure owns 21,010 own shares in the Company.

For further information, please contact:

Photocure  
CFO Erik Dahl  
Tel: +47 450 55 000  
Email: [ed@photocure.com](mailto:ed@photocure.com)

### About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at [www.photocure.com](http://www.photocure.com), [www.hexvix.com](http://www.hexvix.com) or [www.cysview.com](http://www.cysview.com)

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.